A Phase 1/2 study of KK8123 in X-linked hypophosphatemia
Recruiting Phase 1,Phase 2 NCT06525636
Study Description
A First-in-Human Study to Evaluate the Safety and Effects of an Investigational Drug (KK8123) in Adults with X-linked Hypophosphatemia
Study Details
- Registry ID:
- NCT06525636
- Conditions:
- X-linked Hypophosphatemia
- Phase:
- Phase 1,Phase 2
- Target Enrollment:
- 24 participants
- Start Date:
- Age Range:
- 18–65 years
- Healthy Volunteers:
- No
Study Locations (14 sites)
-
Hospital Universitario La Paz
Madrid, Fuencarral-El Pardo, Spain -
Hospital Universitario La Paz
Madrid, Spain -
Hoptial Bictre
Le Kremlin-Bicêtre, Paris, France -
CHU le Kremlin Bicetre
Paris, France -
University of Wuerzburg
Würzburg, Sanderring, Germany -
Universitaetsklinikum Wurzburg
Würzburg, Germany -
The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
Gobowen, Oswestry, United Kingdom -
Institute of Osteology and Biomechanics (IOBM)
Hamburg, Germany -
Yale School of Medicine
New Haven, Connecticut, United States -
Yale Center for XLH/ Yale University School of Medicine
New Haven, Connecticut, United States -
Vanderbilt University Medical Center
Nashville, Tennessee, United States -
Indiana University School of Medicine University Hospital
Indianapolis, Indiana, United States -
Mayo Clinic
Rochester, Minnesota, United States -
University of California - San Francisco
San Francisco, California, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.